IP Library › Granted Patent US 7,585,996

Granted Patent B2

US 7,585,996 · App. 11/901,194 · Granted Sep 8, 2009

Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Assignee: XenoPort, Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,585,996
App. No.: 11/901,194
Granted: Sep 8, 2009
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.

Claims (176)

1. A compound of Formula (I):

a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate of any of the foregoing, wherein:

R 1 is chosen from acyl, substituted acyl, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl;

R 2 and R 3 is chosen from hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; or R 2 and R 3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl ring;

R 4 is chosen from benzyl, substituted benzyl, C 4-7 cycloalkyl, C 3-7 cycloalkylmethyl, and dialkoxymethyl;

R 5 is chosen from hydrogen, hydroxy, mercapto, fluoro, oxo, C 1-4 alkyl, substituted C 1-4 alkyl, aryl, substituted aryl, C 3-6 cycloalkyl, substituted C 3-6 cycloalkyl, heteroaryl, substituted heteroaryl, C 7-9 phenylalkyl, and substituted C 7-9 phenylalkyl;

R 6 and R 7 is chosen from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, aryl, substituted aryl, C 3-6 cycloalkyl, heteroaryl, substituted heteroaryl, C 7-9 phenylalkyl, and substituted C 7-9 phenylalkyl; and

R 8 is chosen from hydrogen, C 1-6 alkyl, substituted C 1-6 alkyl, aryl, substituted aryl, C 3-6 cycloalkyl, substituted C 3-6 cycloalkyl, heteroaryl, substituted heteroaryl, C 7-9 phenylalkyl, and substituted C 7-9 phenylalkyl.

2. The compound of claim 1 , wherein R 1 is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-dimethoxyethyl, 1,1-diethoxyethyl, phenyl, 4-methoxyphenyl, benzyl, phenethyl, styryl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.

3. The compound of claim 1 , wherein R 1 is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl, cyclohexyl, and 3-pyridyl.

4. The compound of claim 1 , wherein R 1 is chosen from propyl, isopropyl, tert-butyl, cyclohexyl, and phenyl.

5. The compound of claim 1 , wherein R 2 is chosen from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, phenyl, and cyclohexyl, and R 3 is hydrogen.

6. The compound of claim 1 , wherein R 2 is chosen from hydrogen, methyl, and isopropyl; and R 3 is hydrogen.

7. The compound of claim 1 , wherein R 3 is hydrogen.

8. The compound of claim 1 , wherein R 4 is chosen from cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and cycloheptylmethyl.

9. The compound of claim 1 , wherein R 4 is chosen from dietihoxymethyl, cyclohexylmethyl, and benzyl.

10. The compound of claim 1 , wherein R 5 is chosen from hydrogen, hydroxy, fluoro, oxo, and 4-chlorophenyl.

11. The compound of claim 1 , wherein R 5 is chosen from hydrogen and hydroxy.

12. The compound of claim 1 , wherein each of R 6 , R 7 , and R 8 is hydrogen.

13. The compound of claim 1 , wherein each of R 6 and R 7 is hydrogen, and R 8 is chosen from 3,5-dichlorobenzyl, 1-(3-chlorophenyl)ethyl, 1-(3,4-dichlorophenyl)ethyl, 1-(3-chloro-4-iodophenyl)ethyl, 1-(4-chloro-3-iodophenyl)ethyl, 3,4-dimethylbenzyl, 1-(2,4-dimethoxyphenyl)ethyl, 1-(2,5-dimethoxyphenyl)ethyl, 1-(2,6-dimethoxyphenyl)ethyl, 1-(3,4-dimethoxyphenyl)ethyl, 1-(3,5-dimethoxyphenyl)ethyl, 1-(3,4,5-trimethoxyphenyl)ethyl, 3-carboxybenzyl, 3-cyanobenzyl, 4-carboxybenzyl, 4-cyanobenzyl, 1-(3-carboxyphenyl)ethyl, 1-(3-cyanophenyl)ethyl, 1-(4-carboxyphenyl)ethyl, 1-(4-cyanophenyl)ethyl, 3-phenylprop-2-yl, 2-(3,4-dichlorophenyl)propyl, 3-(3,4-dichlorophenyl)prop-2-yl, and 3-phenyl-3-hydroxyprop-2-yl.

14. The compound of claim 1 , wherein each of R 6 and R 7 is hydrogen, and R 8 is chosen from 1-(3,4-dichlorophenyl)ethyl, 1-(3-carboxyphenyl)ethyl, 1-(4-carboxyphenyl)ethyl, 3,5-dichlorobenzyl, 3-carboxybenzyl, and 4-carboxybenzyl.

15. The compound of claim 1 , wherein R 1 is chosen from propyl, isopropyl, tert-butyl, cyclohexyl, and phenyl; R 2 is chosen from hydrogen, methyl, and isopropyl; and each of R 3 , R 5 , R 6 , R 7 , and R 8 is hydrogen.

16. A compound chosen from:

3-{[1-isobutanoyloxyethoxy]carbonylamino}propyl(n-butyl)phosphinic acid;

3-{[benzoyloxyethoxy]carbonylamino}propyl(n-butyl)phosphinic acid;

3-{[1-isobutanoyloxymethoxy]carbonylamino}propyl(n-butyl)phosphinic acid;

3-{[benzoyloxymethoxycarbonylamino}propyl(n-butyl)phosphinic acid;

3-{[1-isobutanoyloxyisobutoxy]carbonylamino}propyl(n-butyl)phosphinic acid;

3-{[1-cyclohexanoyloxyethoxy]carbonylamino}propyl(n-butyl)phosphinic acid;

3-{[1-isobutanoyloxyisobutoxy]carbonylamino}propyl(n-butyl)phosphinic acid sodium salt;

3-{[butanoyloxyethoxy]carbonylamino}propyl(n-butyl)phosphinic acid sodium salt; and a pharmaceutically acceptable solvate of any of the foregoing.

17. A pharmaceutical composition comprising a therapeutically effective amount of at least one pharmaceutically acceptable vehicle and at least one compound of Formula (I):

a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate of any of the foregoing, wherein:

R 2 and R 3 is chosen from hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl, or R 2 and R 3 together with the carbon atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl ring;

R 4 is chosen from benzyl, substituted benzyl, C 4-7 cycloalkyl, C 3-7 cycloalkylmethyl, and dialkoxymethyl;

R 6 and R 7 is chosen from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, aryl, substituted aryl, C 3-6 cycloalkyl, heteroaryl, substituted heteroaryl, C 7-9 phenylalkyl, and substituted C 7-9 phenylalkyl; and

18. The pharmaceutical composition of claim 17 , wherein the therapeutically effective amount is effective for treating a disease chosen from mild cognitive impairment, cognitive impairment associated with Alzheimer's disease, depression, anxiety, and epilepsy.

19. The pharmaceutical composition of claim 17 , wherein the pharmaceutical composition is a sustained release oral formulation.

20. A method of treating a disease chosen from a mild cognitive impairment, cognitive impairment associated with Alzheimer's disease, depression, anxiety, and epilepsy in a patient comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 17 .

21. The method of claim 20 , wherein a therapeutically effective concentration of the corresponding 3-aminopropylphosphinic acid analog is maintained in the plasma of the patient for at least about 4 hours after the pharmaceutical composition is orally administered to the patient.

22. A pharmaceutical composition comprising a therapeutically effective amount of at least one pharmaceutically acceptable vehicle and at least one compound chosen from: